Close Menu

NEW YORK (GenomeWeb) – Affymetrix and UK-based XRGenomics are collaborating on the development of new diagnostic tests for neurodegenerative diseases, the companies said today.

Financial and other terms of the agreement were not disclosed.

XRGenomics has used Affymetrix's GeneTitan microarray technology to develop gene expression signatures and find biomarkers for diseases such as Alzheimer's disease.

The firm plans to use the technology to optimize its RNA signatures in large clinical trials involving thousands of patients with cognitive impairment.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

New research shows that scientists need to do a better job of including a wider diversity of African genomes in their analyses, STAT says.

A new paper in Science shows that men are still winning a large majority of the most sought-after NIH grants.

Nature Research and the Estée Lauder Companies are awarding efforts to encourage girls to pursue careers in the STEM fields.

In Science this week: beneficial genetic variants inherited from archaic Neanderthal and Denisovan hominins, and more.